EyePoint Pharmaceuticals Announces U.S. Commercial Launch of YUTIQ™ (fluocinolone acetonide intravitreal implant) 0.18 mg
– YUTIQ Indicated for the Treatment of Chronic Non-Infectious Posterior Segment Uveitis – WATERTOWN, Mass., Feb. 04, 2019 (GLOBE NEWSWIRE) […]